Partnership between Roche and Foundation Medicine, Inc. heralds a new chapter in the use of molecular information to choose the right treatments for cancer patients.
Roche recently acquired a majority stake in Foundation Medicine, Inc. (FMI), the molecular information company, beginning a collaboration that has the potential to bring personalised healthcare in oncology to the next level.
Combining Roche’s deep understanding of cancer biology with FMI’s exceptional sequencing data and real-world genomic information will enable us to better design and understand the results of clinical trials based on molecular information.
From the onset, we really felt that molecular information was going to advance our personalised healthcare strategy by improving the way we deliver diagnostics and therapies to patients.
A piece of cancer tissue half the size of a pea is all that is required to run all the tests needed to get the necessary genomic information. A report is generated which goes back to the treating physician, providing a list of the genomic alterations that are thought to be the drivers for that cancer and an overview of any therapies available which may help to target these alterations.
Founded in 2009, Foundation Medicine, Inc. (FMI) is focused on generating in-depth genomic data on cancers with the aim of providing the treating physician with actionable information and the patient with the most effective treatment available. FMI has comprehensively assessed hundreds of genes known to be associated with cancer, and it has profiled the cancer genomes of more than 60,000 patients with the help of next-generation DNA sequencing.